Donate | Print Page | Contact Us | Report Abuse | Sign In | Join/Renew
The News | ASENT19
Share |

 

ASENT 2019 News

ASENT is pleased to announce that Dr. Robert Temple, MD, CDER’s Deputy Center Director for Clinical Science and Acting Deputy Director of the Office of Drug Evaluation, will deliver a keynote address at the ASENT 2019 Annual Meeting. Dr. Temple will share his knowledge on trial design, new design parameters, outcomes and new approaches using genetics and molecular biology to enrich the clinical studies.

 

 Dr. Temple received his medical degree from the New York University School of Medicine in 1967. In 1972 he joined CDER as a review Medical Officer in the Division of Metabolic and Endocrine Drug Products.  He later moved into the position of Director of the Division of Cardio-Renal Drug Products. 

In his current position, Dr. Temple oversees ODE-1 which is responsible for the regulation of cardio-renal, neuropharmacologic, and psychopharmacologic drug products.  Dr. Temple has a long-standing interest in the design and conduct of clinical trials. He has written extensively on this subject, especially on choice of control group in clinical trials, evaluation of active control trials, trials to evaluate dose-response, and trials using “enrichment” designs.

Dr. Temple’s keynote will take place on Tuesday, March 26, 2019 at 8:00 am, at the Bethesda North Marriott in Rockville, MD. We are pleased to welcome Dr. Temple and hope you will have the opportunity to hear this important presentation.

 

 

American Society for Experimental Neurotherapeutics
230 Kings Highway East, Ste 245
Haddonfield, NJ 08033
p: 833.273.6800
e: jessicasmith.asent@gmail.com

   Connect with Us